AMD Global Telemedicine and Carefluence Announce Strategic Partnership to Enhance Telehealth Interoperability

October 29, 2024 7:00 AM

The collaboration delivers greater value to clients for seamless data exchange, enhanced continuity of care, and improved clinical outcomes.CHELMSFORD, MA / ACCESSWIRE / October 29, 2024 / AMD Global Telemedicine, a pioneer and industry leader in telehealth technology solutions for over 30 years, today announced a strategic partnership with Carefluence, an innovator in interoperability solutions. This collaboration aims to further enhance AMD's...

Read more

Top Atlanta Plastic Surgery Practice, Premier Image Cosmetic & Laser Surgery, Welcomes Jennifer Liechty

October 29, 2024 7:00 AM

Expert nurse practitioner Jennifer Liechty brings advanced facial rejuvenation techniques to Premier Image Cosmetic & Laser SurgeryATLANTA, GA / ACCESSWIRE / October 29, 2024 / Premier Image Cosmetic & Laser Surgery is pleased to announce that Jennifer Liechty, a board-certified Nurse Practitioner, will be joining the practice in Atlanta, GA. This addition to the team strengthens the practice's commitment to providing exceptional facial...

Read more

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024

October 29, 2024 6:00 AM

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2024, after the market closes on Wednesday, November 6, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can...

Read more

BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

October 29, 2024 3:05 AM

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that it has initiated the nationalization process for the filing of a family of patents for the sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases. The patents are 100% owned by BioNxt.Subject to the international Patent Cooperation Treaty ("PCT"), the European Patent Office ("EPO") issued a...

Read more

Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE

October 29, 2024 2:20 AM

RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced the publication of a Plain Language Summary in Future Rare Diseases highlighting findings on PKU GOLIKE ® for phenylketonuria (PKU) management. Titled "The Benefits of a Prolonged-Release Protein Substitute with...

Read more

IRLAB Reports Continued Progress Ahead of the Mesdopetam Phase III Program

October 29, 2024 2:20 AM

GOTHENBURG, SWEDEN / ACCESSWIRE / October 29, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today reports several advances in the preparations for Phase III with its drug candidate mesdopetam. The regulatory authorities in Germany and Portugal are positive about IRLAB's proposed study design for the Phase III...

Read more

Vesalius Cardiovascular Announces Clinical Advisory Board

October 28, 2024 3:00 PM

VANCOUVER, BC / ACCESSWIRE / October 28, 2024 / Vesalius Cardiovascular, a medical device company developing a highly differentiated non-invasive transfemoral system for repair of degenerative mitral valve disease, a very common human heart valve disease, announced today the formation of their Clinical Advisory Board, with the anchor appointment of Dr. John G. Webb.Dr. John G. Webb Dr. John Webb, a global influence in the clinical development of...

Read more

3 Trends I’m Watching in Sustainability

October 28, 2024 11:25 AM

Amalia Adler-Waxman, SVP, Head of Sustainability at TevaNORTHAMPTON, MA / ACCESSWIRE / October 28, 2024 / Teva Pharmaceutical My name is Amalia Adler-Waxman and I'm SVP Head of Sustainability at Teva. Here are the key trends I'm watching in this area.1. Voluntary reporting becomes mandatoryFor years sustainability has been all about transparency. Reporting is the cornerstone of disclosing why, what and how companies advance their long-term...

Read more

Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies

October 28, 2024 10:05 AM

LUND, SE / ACCESSWIRE / October 28, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB); (Nasdaq Stockholm:CANTA) today announced new clinical results from two nadunolimab combination therapy trials in 54 patients. Positive signals of efficacy were documented in the key areas of nadunolimab development, non-small cell lung cancer and gastrointestinal cancers. In addition to the efficacy signals, nadunolimab appeared to counteract oxaliplatin...

Read more

Pharmacy Healthy and Information Technology (PHIT) Collaborative Announces New Executive Director Jeff Rochon

October 28, 2024 9:50 AM

ALEXANDRIA, VA / ACCESSWIRE / October 28, 2024 / The Executive Committee of the Pharmacy Health and Information Technology (PHIT) Collaborative announces a transition in leadership as the founding executive director, Shelly Spiro retires after 14 transformative years of service.Under Shelly's visionary leadership since PHIT's inception in 2010, the Collaborative has become an instrumental force in advancing pharmacy health information...

Read more

MentalHealth.com Launches Mental Health Network

October 28, 2024 9:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / October 28, 2024 / Leading health technology company MentalHealth.com is proud to announce the launch of its Mental Health Network. This newly developed digital resource connects users to over 3,000 therapists across more than 200 regions in the United States, expanding access to nationwide mental health support.MentalHealth.comMentalHealth.com Logo The Mental Health Network was developed by the MentalHealth.com...

Read more

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

October 28, 2024 8:10 AM

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced poster presentations at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 8-10 in Houston, USA.CureVac will present, among other data, extended...

Read more

Tenon Medical(R) Regains Full Compliance with Nasdaq Continued Listing Requirements

October 28, 2024 8:00 AM

Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that it is in compliance with all relevant Nasdaq continued listing Rules. The Company had previously reported non compliance with Nasdaq Rules 5605(b)(1), 5605(c)(2) and 5605(d)(2), with respect to the number of independent directors on its board of directors and certain...

Read more

Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets

October 28, 2024 8:00 AM

Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has secured exclusive licensing rights for an additional 28 multi-regional patent assets from its strategic shareholder and product co-developer, Taiwan Carbon Nano Technology Corporation ("TCNT"). These patents encompass...

Read more

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

October 28, 2024 7:30 AM

Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at the Pain Therapeutics Summit in BostonMIAMI, FL / ACCESSWIRE / October 28, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, announces compelling new preclinical findings showing that Ketamir-2, a novel oral ketamine analog, achieves...

Read more

AGC Biologics Appoints Alberto Santagostino as new Chief Executive Officer

October 28, 2024 7:30 AM

SEATTLE, WA / ACCESSWIRE / October 28, 2024 / AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Alberto Santagostino to Chief Executive Officer and President of AGC Biologics, effective November 1st. Alberto has had a distinguished career in biotech, pharma and managing large-scale global CDMO operations. His expertise and knowledge will lead AGC...

Read more

IRLAB: Invitation to the Interim Report for Q3 2024 Presentation and Webcast

October 28, 2024 7:15 AM

GOTHENBURG, SWEDEN / ACCESSWIRE / October 28, 2024 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January-September 2024. The interim report will be published on Wednesday, October 30 at 07:00 CET.The presentation will be held on...

Read more

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

October 28, 2024 7:00 AM

NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has received notice from the Nasdaq Stock Market LLC ("NASDAQ") informing the Company that it has regained full compliance with the bid price requirement in Listing...

Read more

3Aware and RQM+ Forge Partnership to Enhance MedTech Compliance and Innovation

October 28, 2024 5:30 AM

INDIANAPOLIS, IN / ACCESSWIRE / October 28, 2024 / 3Aware, a pioneer in real-world evidence (RWE) solutions for the medical device industry, is pleased to announce a strategic partnership with RQM+, a leading global MedTech service provider. This collaboration marks a significant step in enhancing regulatory compliance and fostering innovation within the MedTech sector.The partnership will combine 3Aware's advanced aiSurveillance technology with...

Read more

AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis

October 28, 2024 5:15 AM

STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and pain, today announced that it has obtained new positive preclinical efficacy data supporting the continued development of the candidate drug ACD137 within the TrkA-NAM program.The new in vivo data, obtained in a...

Read more